Definiens, Cernostics to develop cancer diagnostic tests

Manjula Puthenedam, PhD, | | Health Imaging | Oncology Imaging
Definiens and Cernostics have entered a partnership to develop a multiplexed assay tool for the diagnosis of cancer.

Cernostics takes a systems approach to tumor analysis, evaluating immune, stromal, stem cell and tumor biomarkers on a single slide while preserving tissue structure. This can help clinicians better understand disease subtypes and help them choose the course of treatment most suited to each patient’s disease state, said Danville, Pa.-based Cernostics.

Cernostics will be using Munich-based Definiens Tissue Studio to develop its cancer diagnostic test, which relies on multiplexed panels of fluorescence biomarkers, added the company.

Manjula Puthenedam, PhD,

Related Content

MRI guidance significantly reduces radiotherapy side effects compared to CT
Interventional procedure often as effective as surgery for difficult-to-treat liver cancer
AI tumor volume estimations could improve prostate cancer treatment strategies
MRI could be 'powerful tool' for guiding surgery decisions in patients with rectal cancer
Breast cancer only visible via MRI is often less aggressive
Breast cancer rates are on the rise, new report reveals

Around the web

Cardiovascular Business
New AI program delivers rapid, accurate echo video assessments

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Radiology Business
Key Medicare reimbursement and No Surprises Act updates from RSNA 2024

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

Cardiovascular Business
Philips, Mayo Clinic using AI to improve cardiac MRI technology

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.